A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Registration Number
- NCT03274492
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1000
- Previously untreated participants with cluster of differentiation 20 (CD20)-positive DLBCL, including one of the following diagnoses by 2016 World Health Organization (WHO) classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS) including germinal center B-cell type, activated B-cell type; T-cell/histiocyte-rich large B-cell lymphoma; Epstein-Barr virus-positive DLBCL, NOS; anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma; human herpesvirus-8 (HHV8)-positive DLBCL, NOS; High-grade B-cell lymphoma with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements (double-hit or triple-hit lymphoma); High-grade B-cell lymphoma, NOS
- Availability of archival or freshly collected tumor tissue before study enrolment
- International Prognostic Index (IPI) score of 2-5
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- Life expectancy greater than or equal to (>/=)12 months
- Left ventricular ejection fraction (LVEF) >/= 50 percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
- Adequate hematologic function
- Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and refrain from donating eggs.
- Male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom and agreement to refrain from donating sperm.
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
- Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
- Prior organ transplantation
- Current Grade greater than (>) 1 peripheral neuropathy by clinical examination
- Demyelinating form of Charcot-Marie-Tooth disease
- History of indolent lymphoma
- History of follicular lymphoma grade 3B
- B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (grey-zone lymphoma)
- Primary mediastinal (thymic) large B-cell lymphoma
- Burkitt lymphoma
- Prior treatment with cytotoxic drugs within 5 years of screening for any condition (example [e.g.], cancer, rheumatoid arthritis) or prior use of any anti-CD20 antibody
- Prior use of any monoclonal antibody within 3 months of the start of Cycle 1
- Prior therapy for DLBCL, with the exception of nodal biopsy
- Corticosteroid use >30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control
- Participants with central nervous system (CNS) lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL
- Vaccination with live vaccines within 28 days prior to the start of Cycle 1
- Any investigational therapy within 28 days prior to the start of Cycle 1
- History of other malignancy that could affect compliance with the protocol or interpretation of results
- Evidence of significant, uncontrolled, concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease
- Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
- History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or significant infections within 2 weeks before the start of Cycle 1
- Clinically significant liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis
- Prior radiotherapy to the mediastinal/pericardial region
- Participants with suspected active or latent tuberculosis
- Positive test results for chronic hepatitis B and hepatitis C infection
- Known history of human immunodeficiency virus (HIV) seropositive status
- Positive results for the human T-lymphotrophic 1 virus (HTLV-1)
- Participants with a history of progressive multifocal leukoencephalopathy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin Polatuzumab Vedotin Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\^2) IV, cyclophosphamide 750 mg/m\^2 IV, and doxorubicin 50 mg/m\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHOP plus Polatuzumab Vedotin Placebo Vincristine Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m\^2 IV, cyclophosphamide 750 mg/m\^2 IV, doxorubicin 50 mg/m\^2 IV, and vincristine 1.4 mg/m\^2 IV (maximum 2 milligrams per dose \[mg/dose\]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHOP plus Polatuzumab Vedotin Placebo Prednisone Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m\^2 IV, cyclophosphamide 750 mg/m\^2 IV, doxorubicin 50 mg/m\^2 IV, and vincristine 1.4 mg/m\^2 IV (maximum 2 milligrams per dose \[mg/dose\]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin Rituximab Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\^2) IV, cyclophosphamide 750 mg/m\^2 IV, and doxorubicin 50 mg/m\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin Vincristine Placebo Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\^2) IV, cyclophosphamide 750 mg/m\^2 IV, and doxorubicin 50 mg/m\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHOP plus Polatuzumab Vedotin Placebo Rituximab Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m\^2 IV, cyclophosphamide 750 mg/m\^2 IV, doxorubicin 50 mg/m\^2 IV, and vincristine 1.4 mg/m\^2 IV (maximum 2 milligrams per dose \[mg/dose\]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHOP plus Polatuzumab Vedotin Placebo Polatuzumab vedotin Placebo Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m\^2 IV, cyclophosphamide 750 mg/m\^2 IV, doxorubicin 50 mg/m\^2 IV, and vincristine 1.4 mg/m\^2 IV (maximum 2 milligrams per dose \[mg/dose\]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin Cyclophosphamide Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\^2) IV, cyclophosphamide 750 mg/m\^2 IV, and doxorubicin 50 mg/m\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin Doxorubicin Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\^2) IV, cyclophosphamide 750 mg/m\^2 IV, and doxorubicin 50 mg/m\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin Prednisone Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\^2) IV, cyclophosphamide 750 mg/m\^2 IV, and doxorubicin 50 mg/m\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHOP plus Polatuzumab Vedotin Placebo Cyclophosphamide Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m\^2 IV, cyclophosphamide 750 mg/m\^2 IV, doxorubicin 50 mg/m\^2 IV, and vincristine 1.4 mg/m\^2 IV (maximum 2 milligrams per dose \[mg/dose\]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8. R-CHOP plus Polatuzumab Vedotin Placebo Doxorubicin Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m\^2 IV, cyclophosphamide 750 mg/m\^2 IV, doxorubicin 50 mg/m\^2 IV, and vincristine 1.4 mg/m\^2 IV (maximum 2 milligrams per dose \[mg/dose\]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\^2 IV will be administered as monotherapy in Cycles 7 and 8.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma From randomization to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs earlier (up to 38 months)
- Secondary Outcome Measures
Name Time Method Functional Assessment of Cancer Treatment/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) Peripheral Neuropathy Score Day 1 of Cycles 1-8 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months) Percentage of Participants With adverse Events (AEs) From randomization to the end of study (up to approximately 65 months) Percentage of Participants With Complete Response (CR) as Assessed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) by Blinded Independent Central Review (BICR) End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 8 [Cycle length=21 days] [up to Week 32]) Event-Free Survival-Efficacy (EFSeff) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma From randomization to first occurrence of disease progression/relapse;or death from any cause;or other primary efficacy reason that leads to initiation of any non-protocol specified antilymphoma treatment(NALT);or residual disease(up to approx 65 months) Percentage of Participants Who are Progression Free as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma 24 months after enrollment (up to approximately 65 months) Serum Concentration of Total Polatuzumab Vedotin Pre-infusion (0 hour [hr]), 0.5 hr post-infusion (infusion duration=90 minutes [min]) on Day 1 of Cycle 1 and 4 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months) Overall Survival From randomization until death from any cause (up to approximately 65 months) Percentage of Participants With CR as Assessed by FDG-PET by Investigator End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 8 [Cycle length=21 days] [up to Week 32]) Disease-Free Survival (DFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma From the date of first occurrence of a documented CR to the date of relapse or death from any cause (up to approximately 65 months) Duration of Response as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma From the date of first occurrence of a documented CR or partial response (PR) to the date of progression, relapse, or death from any cause (up to approximately 65 months) Event-Free Survival-All Causes (EFSall) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma From randomization to disease progression or relapse, or death from any cause, or initiation of any NALT (up to approximately 65 months) Time to Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) Physical Functioning and Fatigue Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); treatment completion visit (TCV)/early treatment termination visit (ETTV) (up to approximately 32 weeks); post-treatment follow-up (FU) visit (up to approximately 65 months) Time to Deterioration in Functional Assessment of Cancer Therapy-Lymphoma Lymphoma Subscale (FACT-Lym LymS) Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months) Percentage of Participants Achieving Meaningful Improvement in EORTC QLQ-C30 Physical Functioning and Fatigue Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months) Percentage of Participants Achieving Meaningful Improvement in FACT-Lym LymS Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months) EORTC QLQ-C30 Treatment-Related Symptoms Score Day 1 of Cycles 1, 2, 3 and 5 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months) Plasma Concentration of Polatuzumab Vedotin Conjugate (Antibody-Conjugated Mono-Methyl Auristatin E [acMMAE]) 0.5 hr post-infusion (infusion duration=90 min) on Day 1 of Cycle 1 and 4 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months) Plasma Concentration of Polatuzumab Vedotin Unconjugated MMAE 0.5 hr post-infusion (infusion duration=90 min) on Day 1 of Cycle 1 and 4 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months) Percentage of Participants With Anti-Drug Antibody (ADA) to Polatuzumab Vedotin Pre-infusion (0 hr) on Day 1 of Cycle 1 and 4 (Cycle length=21 days); TCV/ETTV (up to approximately 32 weeks); post-treatment FU visit (up to approximately 65 months)
Trial Locations
- Locations (216)
Leningrad Regional Clinical Hospital
🇷🇺St Petersburg, Sankt Petersburg, Russian Federation
Complejo Hospitalario de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinic Barcelona
🇪🇸Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Institut Catala d Oncologia Hospitalet
🇪🇸Barcelona, Spain
Hospital San Pedro de Alcantara
🇪🇸Caceres, Spain
Hospital Universitari Dr. Josep Trueta
🇪🇸Girona, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Fundación Jimenez Díaz
🇪🇸Madrid, Spain
Hospital Quiron Madrid
🇪🇸Madrid, Spain
Hospital Universitario Virgen de la Victoria
🇪🇸Malaga, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Universitätsspital Basel Gynäkologie - Onkologie
🇨🇭Basel, Switzerland
Kaohsiung Medical University Hospital, Cancer Center
🇨🇳Kaohsiung, Taiwan
Chi-Mei Hospital, Liouying
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Ankara University Faculty of Medicine Cebeci Hospital
🇹🇷Ankara, Turkey
Ege Üniversitesi Tip Fakültesi
🇹🇷Lzmir, Turkey
Dokuz Eylul Universitesi Tip Fakultesi
🇹🇷Lzmir, Turkey
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
Emory University
🇺🇸Atlanta, Georgia, United States
University of Louisville Hospital
🇺🇸Louisville, Kentucky, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
Washington University
🇺🇸Saint Louis, Missouri, United States
Roswell Park Cancer Institute
🇺🇸Buffalo, New York, United States
Ohio State University
🇺🇸Columbus, Ohio, United States
Oregon HSU
🇺🇸Portland, Oregon, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
Greco-Hainesworth Centers for Research
🇺🇸Chattanooga, Tennessee, United States
University of Utah
🇺🇸Salt Lake City, Utah, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Prince of Wales Hospital
🇦🇺Randwick, New South Wales, Australia
Westmead Hospital
🇦🇺Westmead, New South Wales, Australia
Princess Alexandra Hospital Woolloongabba
🇦🇺Woolloongabba, Queensland, Australia
Austin Hospital
🇦🇺Heidelberg, Victoria, Australia
Fakultni Nemocnice Hradec Kralove (FNHK)
🇨🇿Hradec Kralove, Czechia
Fakultni Nemocnice Kralovske Vinohrady (FNKV)
🇨🇿Prague, Czechia
CHU Amiens - Hopital Sud
🇫🇷Amiens, France
Centre Hospitalier de La Cote Basque
🇫🇷Bayonne, France
Hopital Jean Minjoz
🇫🇷Besancon, France
Hopital Henri Mondor
🇫🇷Creteil, France
Hôpital Albert Michallon
🇫🇷La Tronche, France
Hopital Claude Huriez
🇫🇷Lille, France
Hopital Uni Ire Dupuytren
🇫🇷Limoges, France
Hôpital Saint-Louis
🇫🇷Paris, France
Gh Necker Enfants Malades
🇫🇷Paris, France
Hopital Saint Jean
🇫🇷Perpignan, France
Hopital Haut-Leveque - Centre Francois Magendie
🇫🇷Pessac, France
Centre Hospitalier de Quimper Cornouaille (CHIC)
🇫🇷Quimper Cedex, France
Hopital Pontchaillou
🇫🇷Rennes, France
Centre Henri Becquerel
🇫🇷Rouen, France
Chru de Strasbourg
🇫🇷Strasbourg, France
CH Bretagne Atlantique
🇫🇷Vannes Cedex, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
🇮🇹Torino, Piemonte, Italy
National Cancer Center
🇰🇷Gyeonggi-do, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan, Korea, Republic of
Canterbury Health Laboratories
🇳🇿Christchurch, New Zealand
Wojewódzki Szpital Specjalistyczny im. M. Kopernika
🇵🇱?ód?, Poland
SPZOZ Ministerstwa Spraw Wewn?trznych i Administracji w Poznaniu
🇵🇱Pozna?, Poland
China Medical University Hospital
🇨🇳Taichung, Taiwan
Khmelnytskyi Regional Hospital
🇺🇦Khmelnytskyi, Kharkiv Governorate, Ukraine
Barts Health NHS Trust
🇬🇧London, United Kingdom
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Southern Cancer Center
🇺🇸Daphne, Alabama, United States
City of Hope
🇺🇸Duarte, California, United States
Rocky Mountain Cancer Centers, LLP
🇺🇸Aurora, Colorado, United States
Georgetown University Medical Center
🇺🇸Washington, District of Columbia, United States
Florida Cancer Specialists - Fort Myers (New Hampshire Ct)
🇺🇸Fort Myers, Florida, United States
Florida Cancer Specialists & Research Institute
🇺🇸Saint Petersburg, Florida, United States
Florida Cancer Specialists
🇺🇸West Palm Beach, Florida, United States
Illinois Cancer Specialists
🇺🇸Arlington Heights, Illinois, United States
Ochsner Medical Center
🇺🇸New Orleans, Louisiana, United States
University of Maryland
🇺🇸Baltimore, Maryland, United States
Johns Hopkins University
🇺🇸Baltimore, Maryland, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Karmanos Cancer Center
🇺🇸Detroit, Michigan, United States
Memorial Sloan Kettering Bergen
🇺🇸Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center - Commack
🇺🇸Commack, New York, United States
Memorial Sloan Kettering Cancer Center at Westchester
🇺🇸Harrison, New York, United States
New York University Cancer Cen
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Levine Cancer Institute - Clincal Trials Administration
🇺🇸Charlotte, North Carolina, United States
Oncology/Hematology Care Clinical Trials LLC
🇺🇸Cincinnati, Ohio, United States
University Hospitals Case Medical Center
🇺🇸Cleveland, Ohio, United States
Oncology Associates of Oregon, P.C
🇺🇸Eugene, Oregon, United States
Northwest Cancer Specialists - Portland (SW Barnes Rd)
🇺🇸Portland, Oregon, United States
Hospital of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Medical University of South Carolina Hospital
🇺🇸Charleston, South Carolina, United States
Prisma Health ? Upstate
🇺🇸Greenville, South Carolina, United States
Tennessee Oncology - Nashville
🇺🇸Nashville, Tennessee, United States
Texas Oncology-Austin Midtown
🇺🇸Austin, Texas, United States
Texas Oncology San Antonio Medical Center
🇺🇸San Antonio, Texas, United States
Texas Oncology-Tyler
🇺🇸Tyler, Texas, United States
Oncology Associates of Southwest Virginia, Inc.
🇺🇸Blacksburg, Virginia, United States
Virginia Cancer Specialists, PC
🇺🇸Fairfax, Virginia, United States
West Virginia Uni Med. Center - Robert Byrd Health Science
🇺🇸Morgantown, West Virginia, United States
Concord Repatriation General Hospital
🇦🇺Concord, New South Wales, Australia
St George Hospital
🇦🇺Kigarah, New South Wales, Australia
Calvary Mater Newcastle
🇦🇺Waratah, New South Wales, Australia
Ashford Cancer Center Research
🇦🇺Kurralta Park, South Australia, Australia
The University of Adelaide - The Queen Elizabeth Hospital (TQEH)
🇦🇺Woodville South, South Australia, Australia
Monash Medical Centre
🇦🇺Clayton, Victoria, Australia
Paracelsus Medizinischen Privatuniversitaet-Salzburger Landeskliniken (SALK)
🇦🇹Salzburg, Austria
Medizinische Universität Wien
🇦🇹Wien, Austria
Wiener Gesundheitsverbund ? Klinik Ottakring
🇦🇹Wien, Austria
UZ Gent
🇧🇪Gent, Belgium
CH Jolimont - Lobbes (Jolimont)
🇧🇪Haine-Saint-Paul, Belgium
CHU UCL Mont-Godinne
🇧🇪Mont-godinne, Belgium
Hospital Erasto Gaertner
🇧🇷Curitiba, Paraná, Brazil
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Centro de Hematologia e Hemoterapia - HEMOCENTRO UNICAMP
🇧🇷Campinas, São Paulo, Brazil
Hospital das Clinicas - FMUSP
🇧🇷Sao Paulo, São Paulo, Brazil
University of Alberta Hospital
🇨🇦Edmonton, Alberta, Canada
BC Cancer ? Vancouver
🇨🇦Vancouver, British Columbia, Canada
CancerCare Manitoba (CCMB)
🇨🇦Winnipeg, Manitoba, Canada
The Ottawa Hospital
🇨🇦Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
CIUSSS de l Est de l Ile de Montreal - Hopital Maisonneuve Rosemont
🇨🇦Montreal, Quebec, Canada
CHU de Quebec-Universite Laval
🇨🇦Quebec, Canada
Beijing Cancer Hospital
🇨🇳Beijing, China
The First Hospital of Jilin University
🇨🇳Changchun City, China
Fujian Provincial Cancer Hospital
🇨🇳Fuzhou City, China
Sun Yet-sen University Cancer Center
🇨🇳Guangzhou, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
🇨🇳Hangzhou, China
Jiangsu Cancer Hospital
🇨🇳Nanjing, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai City, China
Shanghai East Hospital, Tongji University
🇨🇳Shanghai City, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
🇨🇳Tianjin City, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjing, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan City, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Fakultni nemocnice Ostrava
🇨🇿Ostrava - Poruba, Czechia
Univerzita Karlova v Praze 1. Lekarska Fakulta
🇨🇿Prague, Czechia
CHU Angers
🇫🇷Angers, France
Institut Bergonie
🇫🇷Bordeaux, France
Institut d'Hématologie de Basse Normandie
🇫🇷Caen, France
CH Metropole de Savoie
🇫🇷CHAMBERY Cedex, France
CHU de Dijon - Hopital le Bocage
🇫🇷Dijon, France
L'Union Mutualiste de la Gestion des Eaux Claires - Institut Daniel Hollard
🇫🇷Grenoble, France
CHD Vendée
🇫🇷La Roche Sur Yon, France
Clinique Victor Hugo - Centre Jean Bernard
🇫🇷Le Mans Cedex 02, France
Hôpital Saint Vincent de Paul
🇫🇷Lille, France
Centre Leon Berard
🇫🇷Lyon, France
CHU Montpellier - Saint ELOI
🇫🇷Montpellier, France
CHU de Nantes - Hotel Dieu
🇫🇷Nantes, France
Centre Antoine Lacassagne
🇫🇷Nice, France
CHU de Nîmes - Hôpital Carémeau
🇫🇷Nimes, France
CHU Lyon Sud - Service Hématologie
🇫🇷Pierre Benite, France
CHU de Poitiers
🇫🇷Poitiers, France
Centre Hospitalier de Saint Brieuc - Hôpital Yves Le Foll
🇫🇷St Brieuc, France
Pôle de Cancérologie ? CHU de Saint?Etienne'
🇫🇷St Priest en Jarez, France
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
🇫🇷Toulouse, France
CHU Bretonneau
🇫🇷Tours, France
CHU de Brabois
🇫🇷Vandoeuvre Les Nancy, France
Vivantes Klinikum Am Urban
🇩🇪Berlin, Germany
Städtisches Klinikum Dessau
🇩🇪Dessau-Roßlau, Germany
Universitätsklinikum Essen
🇩🇪Essen, Germany
Universitaetsklinikum Halle (Saale)
🇩🇪Halle, Germany
Universitaetsklinikum Heidelberg
🇩🇪Heidelberg, Germany
InVO - Institut für Versorgungsforschung in der Onkologie GbR
🇩🇪Koblenz, Germany
Universitatsklinikum Munster
🇩🇪Münster, Germany
Azienda Ospedaliera Papa Giovanni XXIII
🇮🇹Bergamo, Abruzzo, Italy
Communal Institution 'Cherkassy Regional Oncology Dispensary' of the Cherkassy Regional Council
🇺🇦Cherkassy, Chernihiv Governorate, Ukraine
MNE Lviv Territorial Medical Association Clinical Hospital for Palliative Care
🇺🇦Lviv, Chernihiv Governorate, Ukraine
Feofaniya Center of Haematology and Chemotherapy of Haemoblastosis
🇺🇦Kyiv, Volhynian Governorate, Ukraine
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
🇬🇧Cambridge, United Kingdom
East Kent Hospitals University NHS Foundation Trust
🇬🇧Canterbury, United Kingdom
University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary
🇬🇧Leicester, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust. Freeman Hospital
🇬🇧Newcastle upon Tyne, United Kingdom
Oxford University Hospitals NHS Foundation Trust
🇬🇧Oxford, United Kingdom
Hokkaido University Hospital
🇯🇵Hokkaido, Japan
Kobe City Medical Center General Hospital
🇯🇵Hyogo, Japan
Tokai University Hospital
🇯🇵Isehara-shi, Japan
Universita degli Studi Di Brescia - Azienda Ospedaliera Spedali Civili di Brescia
🇮🇹Brescia, Abruzzo, Italy
Universita degli Studi di Roma ''La Sapienza" - Clinica Ematologica
🇮🇹Rome, Abruzzo, Italy
AUSL di Reggio Emilia, IRCCS, P.O. Arcispedale Santa Maria Nuova
🇮🇹Reggio Emilia, Emilia-Romagna, Italy
IRCCS AOU San Martino - IST
🇮🇹Genova, Liguria, Italy
Istituto Nazionale dei Tumori
🇮🇹Monza, Lombardia, Italy
Azienda Ospedaliero Universitaria Maggiore della Carita di Novara
🇮🇹Novara, Piemonte, Italy
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
University Hospital Kyoto Prefectural University of Medicine
🇯🇵Kyoto, Japan
Tohoku University Hospital
🇯🇵Miyagi, Japan
Osaka Metropolitan University Hospital
🇯🇵Osaka, Japan
Osaka University Hospital
🇯🇵Osaka, Japan
Kindai University Hospital
🇯🇵Osaka, Japan
Jichi Medical University Hospital
🇯🇵Tochigi, Japan
National Cancer Center Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Aichi Cancer Center
🇯🇵Aichi, Japan
Chiba Cancer Center
🇯🇵Chiba, Japan
National Cancer Center Hospital East
🇯🇵Chiba, Japan
Chiba University Hospital
🇯🇵Chuo-ku, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Hiroshima University Hospital
🇯🇵Hiroshima, Japan
Auckland City Hospital, Cancer and Blood Research
🇳🇿Auckland, New Zealand
Waikato Hospital
🇳🇿Hamilton, New Zealand
Samodzielny Publiczny Zak?ad Opieki Zdrowotnej Zespó? Szpitali Miejskich w Chorzowie
🇵🇱Chorzów, Poland
PRATIA MCM Kraków
🇵🇱Kraków, Poland
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland